The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...

Sandoz is one of the largest biosimilars players in the world and we believe it is well-positioned to benefit from the fast pace of growth the market is expected to enjoy over the next decade. Sandoz ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart ... and renal or hepatic function occur as well as during acute illness.

The Global Oncology Biosimilars Market is expected to grow at 18.5% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...

India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

Insulin is a hormone that allows glucose in the blood to enter cells, providing them with the energy to function. A lack of adequate insulin plays a key role in the development of diabetes.

Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the Food and Drug Administration. HealthDay News — The U.S. Food and Drug ...

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...

Bengaluru: BioconBiologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., has announced that YESINTEK (ustekinumab-kfce) is now available to patients in the United ...